Low Testosterone & Mortality Risk: Insights from Royal Medical Centers

Last Updated: OCTOBER 2026

Men with total testosterone below 300 ng/dL have a 2.4-fold increased risk of all-cause mortality, specifically cardiovascular mortality, compared to men with levels above 600 ng/dL, according to a large prospective study published in the Journal of Clinical Endocrinology & Metabolism (Hyde et al., 2018). This stark reality underscores the critical role testosterone plays beyond just libido and muscle mass, extending into fundamental aspects of metabolic and cardiovascular health. Royal Medical Centers (RMC) positions itself as a comprehensive provider aiming to address these deficiencies, offering both in-person and telehealth options for men seeking testosterone replacement therapy (TRT).

Royal Medical Centers: A Hybrid Approach to TRT

Royal Medical Centers (RMC) operates on a hybrid model, combining the accessibility of telehealth with the option for in-person consultations and physical exams where available. This approach aims to bridge the gap between purely online clinics and traditional endocrinology practices, offering a more personalized experience that can be crucial for TRT. RMC focuses on a holistic view of men’s health, extending beyond just testosterone levels to include general wellness and age management protocols.

Their philosophy centers on comprehensive lab analysis and symptom-based treatment, rather than relying solely on arbitrary numerical cutoffs. This is particularly relevant given that the frequently cited lower bound for “normal” testosterone, often around 264 ng/dL, was largely calibrated using data from the 1970s that included men with various comorbidities and an aging population. This historical context means that while a level below this threshold is certainly indicative of hypogonadism, many men experiencing significant symptoms of low T may fall into a “low normal” range (e.g., 300-500 ng/dL) where treatment can still be clinically beneficial and symptom-improving. As such, RMC’s protocols often consider symptomatic presentation alongside bloodwork, reflecting a more patient-centric model.

TRT Protocols and Ancillary Medications

RMC’s TRT protocols typically involve injectable testosterone esters, primarily testosterone cypionate or enanthate, which are well-established for their efficacy and stable blood levels.

Testosterone Esters

• Testosterone Cypionate/Enanthate: The most common protocol involves subcutaneous or intramuscular injections of 100–200mg testosterone per week, typically split into two doses (e.g., 50–100mg twice weekly). This frequency helps maintain more stable serum testosterone levels and minimizes potential fluctuations, which can lead to symptom variability. The goal is to elevate total testosterone levels into a physiological range of 700–1000 ng/dL and free testosterone into the optimal range of 15–25 pg/mL, reducing symptoms such as fatigue, low libido, erectile dysfunction, and mood disturbances. The T-Trials, a series of seven coordinated, double-blind, placebo-controlled trials, demonstrated that testosterone treatment significantly improved sexual function, mood, and walking distance in older men with low testosterone (Snyder et al., 2016).

Ancillary Medications

RMC understands that effective TRT often requires more than just testosterone. They integrate ancillary medications to manage potential side effects and optimize overall hormonal balance.

• Human Chorionic Gonadotropin (HCG): HCG is commonly prescribed alongside testosterone to mitigate testicular atrophy and preserve fertility. By mimicking Luteinizing Hormone (LH), HCG stimulates the Leydig cells in the testes to produce endogenous testosterone, preventing the shutdown of the Hypothalamic-Pituitary-Gonadal (HPG) axis induced by exogenous testosterone. Typical dosages range from 500–1000 IU per week, administered subcutaneously, often split into 2-3 injections. This allows for sustained testicular function and prevents the testes from shrinking.

• Anastrozole (Aromatase Inhibitor): For some individuals, testosterone can convert into estradiol (E2) via the aromatase enzyme, leading to elevated E2 levels. High E2 can cause side effects such as gynecomastia, water retention, and mood swings. RMC may prescribe anastrozole, an aromatase inhibitor, to manage E2 levels. Common dosages are 0.25–0.5mg, 1-2 times per week, adjusted based on lab results and symptoms. The aim is to keep E2 within a healthy physiological range, typically 20–40 pg/mL on TRT, ensuring symptom control without crashing E2, which can lead to joint pain, libido issues, and bone density concerns.

• Enclomiphene: For men who wish to avoid exogenous testosterone injections or preserve natural testosterone production while boosting levels, RMC may offer enclomiphene. Enclomiphene is a selective estrogen receptor modulator (SERM) that blocks estrogen’s negative feedback at the hypothalamus and pituitary, leading to increased Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) production. This, in turn, stimulates the testes to produce more testosterone. A typical dose is 12.5–25mg daily or every other day. Enclomiphene offers an alternative for men seeking to raise testosterone while maintaining testicular size and fertility without direct testosterone administration.

Lab Monitoring and Therapeutic Targets

Regular lab monitoring is a cornerstone of responsible TRT. RMC emphasizes comprehensive blood panels at baseline and throughout treatment to ensure safety and efficacy.

• Total Testosterone: Target 700–1000 ng/dL.
• Free Testosterone: Target 15–25 pg/mL.
• Estradiol (E2): Target 20–40 pg/mL (sensitive assay).
• Hematocrit: Below 50%. Elevated hematocrit can increase the risk of cardiovascular events and requires careful management, often through dose adjustments or therapeutic phlebotomy.
• Prostate-Specific Antigen (PSA): Monitored for prostate health, especially in older men.
• Lipid Panel and Liver Enzymes: Checked periodically to assess overall metabolic health.

“The goal of testosterone therapy is to restore serum testosterone levels to the mid-normal range (e.g., 400-700 ng/dL) and to improve symptoms of testosterone deficiency,” as stated in the American Urological Association (AUA) Guideline on Testosterone Deficiency (Mulhall et al., 2018). RMC aims for the higher end of this range, recognizing that symptom resolution often correlates with optimized, rather than merely “normal,” levels.

Patient Experience and Accessibility

RMC’s hybrid model aims to provide flexibility and robust clinical oversight.

Initial Consultation and Labs

The process typically begins with an initial consultation, often telehealth, followed by comprehensive lab work. RMC facilitates lab testing through partner networks, making it convenient for patients nationwide. These initial labs are crucial for diagnosing hypogonadism and ruling out other underlying conditions.

Doctor Consultations and Follow-ups

Once labs are reviewed, patients have a detailed consultation with an RMC physician to discuss results, symptoms, and treatment options. Follow-up consultations are regularly scheduled, often quarterly, to monitor progress, address any side effects, and adjust protocols as needed. This ongoing medical supervision is critical for safe and effective TRT.

Pharmacy and Refills

Medications are typically shipped directly to the patient’s home from compounding pharmacies RMC partners with. This streamlines the refill process and ensures consistent access to prescribed treatments.

Cost and Value Proposition

The cost of TRT can vary significantly between providers. RMC’s pricing structure reflects its comprehensive approach, including physician consultations, lab reviews, and medication management. While specific costs can fluctuate based on individual protocols and ancillary medications, RMC generally falls into a competitive middle ground when considering the level of oversight provided.

Typical Cost Comparison for TRT Providers